Spruce Biosciences Spins Off CRHX‑101 into Adrenyx Biosciences – Harbour BioMed‑Partnered CAH Antibody Program Targets Nasdaq Listing in H1 2027

Fineline Cube
4 Min Read
Summarize with AI

Harbour BioMed (HKG: 2142) announced that its partner Spruce Biosciences (NASDAQ: SPRB) has spun off the CRHX‑101 (HBM9013/HAT001/SPR‑202) program into Adrenyx Biosciences, Inc., a newly established wholly‑owned subsidiary of Spruce. The subsidiary is expected to be listed on Nasdaq in the first half of 2027.

- Advertisement -

Spin‑Off Snapshot

ItemDetail
Announcing CompanyHarbour BioMed (HKG: 2142)
PartnerSpruce Biosciences (NASDAQ: SPRB)
New EntityAdrenyx Biosciences, Inc. – wholly‑owned subsidiary of Spruce
Asset TransferredCRHX‑101 (HBM9013 / HAT001 / SPR‑202) program
Modality / IndicationMonoclonal antibody for congenital adrenal hyperplasia (CAH)
Planned ListingNasdaq, first half of 2027
Next StepsSubmit IND application to US FDA, then initiate clinical development
Announcement Date18 Nov 2026

Drug Profile & Partnership Background

  • Molecule: CRHX‑101, a monoclonal antibody designed and developed for the treatment of congenital adrenal hyperplasia (CAH) — a rare, inherited disorder of adrenal steroidogenesis most commonly caused by 21‑hydroxylase deficiency, for which treatment has long centered on glucocorticoid replacement with risks of both over‑ and under‑treatment.
  • Asset Lineage: The program carries a multi‑code history — HBM9013 / HAT001 / SPR‑202 — reflecting its origin within Harbour BioMed’s antibody platform and subsequent development by Spruce.
  • Licensing Foundation: In January 2025, HBM Alpha Therapeutics, a subsidiary of Harbour BioMed, entered into a collaboration and license agreement with Spruce, granting Spruce exclusive global rights to develop and commercialize CRHX‑101 outside of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).
  • Regulatory Pathway: Adrenyx plans to submit an Investigational New Drug (IND) application for CRHX‑101 to the US FDA and subsequently initiate clinical development under the new subsidiary.
  • Undisclosed Elements: Financial terms of the spin‑off, capitalization of Adrenyx, and target indication sequencing were not disclosed in the announcement.

Market Impact & Outlook

  • Ring‑Fenced Value Creation: Housing CRHX‑101 in a dedicated subsidiary separates the CAH program’s development risk and value from Spruce’s broader operations — a structure designed to give investors direct exposure to the asset ahead of the planned 2027 Nasdaq listing.
  • Rare Endocrine Opportunity: As a monoclonal antibody candidate, CRHX‑101 represents a biologic approach in CAH, a rare endocrine indication dominated by hormonal replacement therapy — positioning Adrenyx in an underserved market with limited targeted treatment options.
  • Harbour BioMed Royalty Optionality: The spin‑off preserves the economics of Harbour BioMed’s 2025 out‑licensing agreement for ex‑Greater China rights, while the company retains development and commercialization of the asset within Greater China.
  • Listing Timeline: The expected Nasdaq listing in H1 2027 would create a newly independent, CAH‑focused public company; timing remains subject to market conditions and IND progression.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the spin‑off of the CRHX‑101 program into Adrenyx Biosciences, the planned IND submission to the FDA, subsequent clinical development, and the expected Nasdaq listing in the first half of 2027. Actual results may differ materially due to risks including regulatory review of the IND, clinical outcomes, capital markets conditions affecting the listing timeline, and the inherent uncertainty of early‑stage biologic development in rare endocrine disorders.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *